Markets:

Overview

News

Currencies

International

Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

29.78 -1.75 (-5.55%)

Streaming Delayed Price Updated: 10:57 AM EDT, Sep 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 ↗

December 11, 2025

These stocks are underperforming the market this year, but that trend may not last for long.

Via The Motley Fool

Topics Artificial Intelligence ETFs

What's Up With The Jump In Viking Therapeutics Stock? ↗

December 04, 2025

Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from the wider excitement in obesity treatment area and...

Via Benzinga

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 ↗

November 27, 2025

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.

Via The Motley Fool

Retail Traders Crown Novo Nordisk As Long-Term Weight Loss King — Even As Eli Lilly Hits $1T And Viking Fans Tout ‘M&A Prize’ ↗

November 25, 2025

Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector.

Via Stocktwits

Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? ↗

November 06, 2025

Via Stocktwits

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera ↗

October 30, 2025

Via Stocktwits

2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon ↗

November 22, 2025

For those with decades left in their investing journey, these top healthcare stocks could be worthy portfolio contenders.

Via The Motley Fool

Topics Intellectual Property

3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential ↗

November 21, 2025

These stocks have market caps of around $4 billion and $5 billion, and they could potentially double or triple in size in the long run.

Via The Motley Fool

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

November 19, 2025

These stocks both have advanced in the double-digits in recent months.

Via The Motley Fool

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

Via The Motley Fool

Topics Regulatory Compliance

2 No-Brainer Healthcare Stocks to Buy Now ↗

November 18, 2025

These two healthcare stocks scan as bargains right now.

Via The Motley Fool

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play ↗

November 13, 2025

Canaccord said Viking’s obesity pipeline is worth far more than the current valuation.

Via Stocktwits

‘Somebody Knows Something:’ Viking Therapeutics Stock Pops To Nearly 3-Month High As Retail Traders Intensely Speculate On M&A Scenarios ↗

November 11, 2025

Via Stocktwits

AMD, Oklo, AppLovin Corp, Viking Therapeutics And Novo Nordisk: Why These 5 Stocks Are On Investors' Radars Today ↗

November 11, 2025

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 inching up 0.2% to 6,846.61.

Via Benzinga

Topics Stocks

2 Monster Stocks in the Making ↗

November 10, 2025

There might still be time to get in on the ground floor.

Via The Motley Fool

Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith ↗

November 09, 2025

Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.

Via Stocktwits

Is There a Future for Viking Therapeutics? ↗

November 09, 2025

The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.

Via The Motley Fool

The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. ↗

November 07, 2025

The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.

Via Investor's Business Daily

Topics Government

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain ↗

November 05, 2025

Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden Cross.

Via Benzinga

Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils ↗

November 05, 2025

Zoom Communications is a good company, Cramer says. Still, he advises, "take a pass." Plus: Viking Therapeutics, Profrac and Altria.

Via Benzinga

Here's Why Shares in Viking Therapeutics Shot Higher in October ↗

November 05, 2025

Three factors took Viking's shares higher in the month.

Via The Motley Fool

Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets. ↗

November 04, 2025

It's a great idea to watch the latest moves of this expert investor.

Via The Motley Fool

Topics Artificial Intelligence

Prediction: The Next Eli Lilly Might Already Be Trading Under $50 ↗

November 03, 2025

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Via The Motley Fool

Should You Buy Viking Therapeutics Before Nov. 5? ↗

November 02, 2025

Viking's stock surged in one trading session after a positive clinical trial report last year.

Via The Motley Fool

3 Promising Growth Stocks That Are Down Around 60% From Their Highs ↗

October 31, 2025

These stocks may be down as of late, but investors shouldn't count them out in the long run.

Via The Motley Fool

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise ↗

October 31, 2025

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Via Stocktwits

10 Health Care Stocks Whale Activity In Today's Session ↗

October 30, 2025

Via Benzinga

Viking Therapeutics: High Risk, High Reward Play ↗

October 27, 2025

Via MarketBeat

Here's Why This Obesity Drug Company's Share Price Soared Today ↗

October 23, 2025

The company had positive updates on its clinical trials.

Via The Motley Fool

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.